Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
The Team
Partners
Distributors
Compliance
Careers
Technology
Our Science
NETs Platform
SubB2M Platform
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Resources
Business Development
Products
Our Products
EXO-NET® Pan-Exosome
Product Overview
Technical Information
Data & Figures
Ordering
hTERT ICC Test
Pipeline
Development Pipeline
SubB2M CA15-3
SubB2M CA125
Exo-Ovarian Cancer Test
Exosome Therapeutics
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
News & Events
INOVIQ in the News
Conferences & Events
Contact
Contact Us
Subscribe to Email Alerts
Analyst Reports
Heading &
Sub-heading can be edited through HQI
Investors
>
Analyst Reports
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
Analyst Reports
Filter by Year:
2024
2023
2022
14-Dec-2022
OC97 study confirms EXO-NET utility for EV biomarker discovery
29-Nov-2022
EXO-NET kicks off in US; exosome work centralised in Melbourne
7-Nov-2022
MST Access: 1 1QFY23 closes with healthy cash balance
19-Oct-2022
MST Access: IIQ agrees to develop SubB2M test targeting pan-cancer diagnostic
25-Aug-2022
MST Access: Next-Gen Precision Diagnostics
1